Short Interest in DARA Biosciences Declines By 26.1% (DARA)
DARA Biosciences (NASDAQ:DARA) was the target of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,208,309 shares, a drop of 26.1% from the July 31st total of 1,633,997 shares, American Banking and Market News reports. Based on an average daily volume of 481,386 shares, the days-to-cover ratio is currently 2.5 days. Currently, 15.7% of the company’s shares are sold short.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of DARA Biosciences in a research note on Wednesday, August 13th. They now have a $1.75 price target on the stock.
DARA Biosciences (NASDAQ:DARA) opened at 1.21 on Friday. DARA Biosciences has a 1-year low of $1.02 and a 1-year high of $4.40. The stock has a 50-day moving average of $1.29 and a 200-day moving average of $1.81. The company’s market cap is $23.6 million.
DARA Biosciences (NASDAQ:DARA) last announced its earnings results on Tuesday, August 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.27. Analysts expect that DARA Biosciences will post $-0.73 EPS for the current fiscal year.
DARA BioSciences, Inc is a specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.